4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
PTC Therapeutics, Inc. authorized a share repurchase program under which it may repurchase up to $500 million of outstanding common stock, subject to market conditions. Purchases may occur from time to time at management's discretion.
PTC Therapeutics raised 2026 product revenue guidance to $960 to $990 million, expects cash flow breakeven in 2026, and plans ST920’s rolling BLA submission for Q4 2026 with potential approval and launch in 2027.
Ptc Therapeutics, Inc. acquired assets primarily related to ST-920 from Sangamo Therapeutics, Inc. in September 2026. Net income was $29.0 million for the nine months ended September 30, 2026, and Sephience generated $181.9 million in net sales during the three months ended September 30, 2026.
PTC Therapeutics reported Q3 2026 total revenue of $358 million, including $276 million product revenue, and raised 2026 total revenue guidance to $1.29 to $1.32 billion and product revenue guidance to $960 to $990 million. Sephience revenue was $182 million.
PTC Therapeutics completed its acquisition of ST-920 from Sangamo Therapeutics, a one-time administered AAV gene therapy candidate for Fabry disease, and expects its rolling BLA submission to FDA for accelerated approval to be completed in Q4 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| active patients worldwide | 2,000 | as of September 30, 2026 | — |
| Non-GAAP R&D expenses non-GAAP | 94.9M | the third quarter of 2026 | — |
|
|
|||
| Non-GAAP SG&A expenses non-GAAP | 66.7M | the third quarter of 2026 | — |
|
|
|||
| Sephience net product revenues | $181.89M | FY2026 Q3 | +829.7% |
|
|
|||
| Total net product revenue across the commercial portfolio | $275.89M | FY2026 Q3 | +110.7% |
|
|
|||
| Translarna net product revenues | $48.51M | FY2026 Q3 | -4.3% |
|
|
|||
| Shares issued and outstanding | 83,327,286 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTCT
this stock
Ptc Therapeutics, Inc.
|
$5.30B | -16.4% | +36.2% | — | 9.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
PTC Therapeutics, Inc. authorized a share repurchase program under which it may repurchase up to $500 million of outstanding common stock, subject to market conditions. Purchases may occur from time to time at management's discretion.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTCT | -3.0% | +7.2% | -6.2% | +5.9% | -16.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -5.6% | +8.3% | -6.7% | +6.1% | -27.0% |
